Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.

Authors

• Maysa M Abu-Khalaf
• Stephen Windsor
• Keita Ebisu
• Saritha Salikooti
• Gowri Ananthanarayanan
• Gina G Chung
• Michael P DiGiovanna
• Bruce G Haffty
• Martin Abrams
• Leonard R Farber
• Arlene D Hsu
• Michael Reiss
• Daniel Zelterman
• Barbara A Burtness

Publication/Presentation Date

1-1-2005

Abstract

OBJECTIVES: This study evaluated the safety and efficacy of dose-dense and -intense sequential doxorubicin (A), paclitaxel (T) and cyclophosphamide (C) as adjuvant therapy for breast cancer (BC) with >or=4 ipsilateral axillary lymph nodes.

METHODS: Patients were recruited after BC surgery if >or=4 axillary nodes were involved by metastatic cancer. Planned treatment was A 90 mg/m(2) three times every 14 days (q14d x 3), T 250 mg/m(2) q14d x 3 and C 3 g/m(2) q14d x 3 combined with filgrastim support.

RESULTS: The study enrolled 85 eligible patients. The median number of lymph nodes involved was 9. Mean dose intensity was >94% of planned for each drug. Common grade 3 toxicities included nausea and/or vomiting (24%), mucositis (18%), neuropathy (16%), palmar-plantar erythrodysesthesia (12%), myalgia (6%) and arthralgia (6%). Grade 3/4 neutropenia occurred in 77 (91%) patients, and 32 (38%) patients had neutropenic fever. One patient developed acute leukemia. Sixty-nine (81%) patients are alive, and 59 (69%) patients are alive and free of distant disease at a median follow-up of 5 years.

CONCLUSIONS: ATC is a feasible regimen for adjuvant therapy of high-risk BC, with a relatively low rate of relapse at the 5-year follow up.

Volume

69

Issue

5

First Page

372

Last Page

383

ISSN

0030-2414

Published In/Presented At

Abu-Khalaf, M. M., Windsor, S., Ebisu, K., Salikooti, S., Ananthanarayanan, G., Chung, G. G., DiGiovanna, M. P., Haffty, B. G., Abrams, M., Farber, L. R., Hsu, A. D., Reiss, M., Zelterman, D., & Burtness, B. A. (2005). Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology, 69(5), 372–383. https://doi.org/10.1159/000089991

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

16319508

Department(s)

Administration and Leadership

Document Type

Article